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Abstract
Aims—Association mapping with lymphoblastoid cell lines (LCLs) is a promising approach in
pharmacogenomics research, and in the current study we utilize this model to perform association
mapping for 29 chemotherapy drugs.
Materials and Methods—Currently, we use LCLs to perform genome-wide association
mapping of the cytotoxic response of 520 European Americans to 29 different anticancer drugs,
the largest LCL study to date. A novel association approach using a multivariate analysis of
covariance design was employed with the software program MAGWAS, testing for differences in
the dose-response profiles between genotypes without making assumptions about the response
curve or the biological mode of association. Additionally, by classifying 25 of the 29 drugs into 8
families according to structural and mechanistic relationships, MAGWAS was used to test for
associations that were shared across each drug family. Finally, a unique algorithm using
multivariate responses and multiple linear regressions across pairs of response curves was used for
unsupervised clustering of drugs.
Results—Among the single drug studies, suggestive associations were obtained for 18 loci, 12
within/near genes. Three of these, MED12L, CHN2 and MGMT, have been previously implicated
in cancer pharmacogenomics. The drug family associations resulted in 4 additional suggestive loci
(3 contained within/near genes). One of these genes, HDAC4, associated with the DNA alkylating
agents, shows possible clinical interactions with temozolomide. For the drug clustering analysis,
18 of 25 drugs clustered into the appropriate family.
Conclusions—This study demonstrates the utility of LCLs for identifying genes having clinical
importance in drug response, for assigning unclassified agents to specific drug families, and
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Introduction
The identification of genetic variants that affect drug response (pharmacogenomics) is a
high priority in human genetics, and has yielded a large number of translational successes
[1]. While progress in this field has been encouraging, there are limitations in mapping dose
response outcomes that impede discovery of new genes/variants associated with drug
response. First, pharmacogenomic studies are often nested within clinical trials. Although
this is the most direct approach for assessing associations with clinical outcomes, it is
subject to a number of limitations, including small sample sizes (often restricting testing to a
small set of genetic variants determined a priori), suboptimal study designs (since trials are
rarely designed for genetic aims), confounding effects from variability in patient treatment
and ethical restrictions in experimental manipulation [2]. These restrictions also influence
the availability of patient cohorts for replication assessment.
These limitations have prompted the use of lymphoblastoid cell lines (LCLs) as an in vitro
model of dose response for cytotoxic chemotherapy drugs [3-5]. There are a number of
advantages that motivate the use of LCLs as a model of cytotoxic response. First, because
LCLs can be derived from healthy individuals, there is no limitation to sample size, allowing
studies to be powered for genome-wide associations. Additionally, family-based samples
can be used as a powerful tool for estimating heritability and detecting genetic associations.
Moreover, because the drug exposure is controlled, there is no confounding due to imprecise
measures of exposure, concomitant medications, etc. Finally, with the use of robotics for
high-throughput phenotyping, this model can facilitate rapid discovery of genetic
associations for response to a large number of drugs.
Previous studies with LCLs have shown promising results, with success in both linkage and
association studies [6-11]. For example, it has been used to assess the heritability of a
number of dose-response outcomes [4, 12], and to successfully detect genetic associations of
clinical relevance, with notable instances being in head and neck cancer [13] and
temozolomide response [10]. Additionally, similarity in dose response has been seen across
drugs within a single drug family [14], reinforcing the potential of the model to categorize
responses as a function of mechanism of action. The use of the LCL model system in
pharmacogenomics has been reviewed elsewhere [5].
In a previous study [12], we used LCL dose response assays in family-based cell lines,
derived from the Centre d’Etude du Polymorphisme Humain (CEPH) reference population
[15], to assess the heritability of differential dose response for a range of FDA-approved
cytotoxic chemotherapy drugs. The drugs were originally selected for this study because
they were commonly prescribed in modern clinical practice, did not require in vivo
activation, were not hormone therapies, and were soluble at the concentrations necessary to
generate a dynamic range of cytotoxic activity. This study showed that dose response was
highly heritable for many drugs, and was modestly heritable for all drugs. This was an
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important first step, as establishing heritability of a given trait is a necessary (but not
sufficient) step in gene mapping. In this first study, we performed linkage analysis to
identify regions that may be associated with the dose response outcomes, but as the study
was underpowered and the linkage peaks identified were generally very broad, we have
adopted an association approach for fine mapping.
In addition, simulation studies have demonstrated that modeling the vector of responses
across drug concentrations jointly can be more powerful than previously used methods in the
detection of differences in dose-response profiles between genotypes [16]. Here, we report
the results from applying this method to real data in genome-wide association mapping for a
cohort of LCLs exposed to 29 cancer drugs. In addition, similarity of dose-response profiles
in LCLs could be used to classify drugs according to known mechanisms of action using no
a priori knowledge, demonstrating the possibility of using LCLs to assign novel cancer
agents to known drug classes.
Materials and Methods
Phenotype and Genotype Data Collection
520 Epstein-Barr virus immortalized LCLs were derived from unrelated Caucasian
participants of the Cholesterol and Pharmacogenetics (CAP) clinical trial, as described in
detail in [18]. Alamar blue assays were used to assess the drug response for all cell lines,
across all drugs. All of the drugs (including dasatinib and sunitinib) demonstrated cell
killing in this system. The system would not necessarily be a predictor of isolated b-call
toxicity in a patient, but rather is used as a cell autonomous system for evaluating drug
effect. LCLs were cultured at 37°C and under 5% CO2 using RPMI medium 1640
containing 2 mM L-glutamine (Gibco) and 15% fetal bovine serum (Sigma), with no media
antibiotics. Each cell line was seeded on two 384 well plates, 4000 cells/well, with each
plate having only one LCL. These two plate formats were for separate experiments, with
LCL viability measurements taken after exposure 14 anticancer drugs on the first plate
format and 15 on the second. With each plate format, LCLs were exposed to six
concentrations for each drug. All drugs were assayed on all cell lines except for 2 drugs due
to technical problems (299 cell lines for 5- fluorouracil and 221 for nilotinib). All drugs and
concentrations used in the current study are given in Supplementary Table 1. To estimate
laboratory reproducibility, a subset of 18 and 19 LCLs were each assayed twice on the first
and second plate formats, respectively, where each replicate was performed on a different
laboratory day.
In addition, every plate also included controls for background fluorescence signal and drug
vehicle. Background signal was estimated from viability readings for LCLs exposed to a
lethal dose of 10% dimethyl sulfoxide (DMSO). Drug vehicle effects were assessed by
exposing cells to vehicle only (water or DMSO at 0.01, 0.1, 1 and 2 percent). Every
observation for each plate (for both controls and drug exposures) was performed in 2X2
quadruplicates. Handling of the resulting 413,568 wells was automated using a Tecan
EVO150 (Tecan Group Ltd) with a 96 head MultiChannel Arm™. All plates were incubated
for 72 hours, dyed with Alamar Blue (Biosource International) and incubated for another 24
hours. After incubation, an Infinite F200 microplate reader with Connect Stacker (Tecan
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Group Ltd) and iControl software (Version 1.6) was used to measure fluorescence intensity
at EX535nm and EM595nm. The resulting raw fluorescence units (RFUs) are proportional
to the concentration of living cells in each well.
All individuals in the CAP study were previously genotyped for either 314,621 or 620,901
SNPs, using HumanHap300 bead chip or HumanQuad610 bead chip platforms, respectively,
as previously described [17, 18]. These markers were used to impute 2.5 million SNPs from
HapMap Release 22, using the Caucasian CEPH reference population and the software
program MACH [19], as previously described [17].
A five-stage quality control (QC) pipeline was implemented on cytotoxicity data. This
pipeline is based on common sources of laboratory confounding, and is described in more
detail in the accompanying Supporting Information. In addition, several variables were used
as covariates to correct for potential sources of confounding, including LCL growth rate,
temperature during fluorescence intensity measurements, and experimental batch. These are
explained in more detail in the Supporting Information. While there was a range in
reproducibility and quality across drugs (as expected in such a high throughput experiment).
The correlations between replicates for each drug is listed in Supplemental Table 2.
Additionally, measures of reproducibility are shown in the Supplemental information. Raw
data and quality control filtered data are both included in the supplement for transparency
(Supplemental Figures 1-4).
Genotypic quality control
The software program PLINK was used to filter out SNPs whose genotyping rate was below
90%, whose minor allele frequency was below 0.05 or whose p-value from a Hardy-
Weinberg test for equilibrium was below 10−5 [20]. These filtering steps left, 2,100,684
SNPs available for association analysis. The possibility for substructure in the filtered
genetic data was assessed using principal component analysis (PCA). PLINK was used to
prune SNPs in high linkage disequilibrium (LD) prior to the principle components analysis
[21]. Specifically, a window of 50 SNPs, a step size of 5 SNPs and a pairwise r-squared
threshold of 0.7 was used. This resulted in approximately 81% of the remaining SNPs being
removed for PCA, leaving a total of 395,033 SNPs available for principal component
analysis. PCA was performed on the remaining SNPs using the software package
EIGENSTRAT [22]. The LD pruning was used only for the PCA analysis, and was not used
as a filter for association analysis. Association analysis was performed on the complete set
of 2,100,684 SNPs that passed QC.
Supplemental Figure 5 shows a scatter plot of the first two principal components (PCs),
revealing two distinct, non-overlapping main groups, each containing over 230 individuals,
with three smaller groups containing between 1 and 9 individuals. The two larger groups
may be due to differences in imputation quality between the 314k and 620k chip sets. To
confirm this, the PCA was repeated on the un-imputed data (only the markers that were
directly genotyped), and the results are shown in Supplemental Figure 6. These results
confirm that there is not evidence of population substructure, or strong clusters in the un-
imputed data. Because we are using the imputed markers in the association mapping, we
used the components from the PCA with the imputed markers for the association analysis
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(as confounding could occur based on the different imputation quality and allele
frequencies). The meaning of the smaller, “outlier” groups is not known, but these outliers
were removed from all subsequent association analysis and PCA was run on the remaining
individuals. Using a multivariate analysis of covariance (MANCOVA) design, with the
vector of mean viabilities at each drug concentration as the response, the first, second and
third PCs were found to be significant (p < 0.05) in 24, 6 and 1 of the 29 drugs, respectively,
so these PCs were used as covariates in association and in clustering analysis. While
included too many components can be a concern (in both masking true signals and over-
parameterizing the model), the significance test is a relatively standard approach for
choosing covariates, and this resulted in a relatively small number of components to include
in the model. Additionally, since these components were significant across the vast majority
of drugs tested, it is likely that they represent confounding and not true signal.
Association analysis
Association mapping was performed using a multivariate analysis of covariance
(MANCOVA) design, with the rationale that modeling the vector of normalized responses
jointly provides more information than a single summary measure, such as half-maximal
inhibitory concentrations (IC50). Simulation studies have shown this method to be both
robust to differences in dose-response profiles between genotypes and powerful in the
detection of true biological signals [16, 23]. The model used in association for any drug d at
and SNP s is:
(1)
where Yi is the vector of normalized responses (across the six concentrations for d) for the jth
j individual having genotype i on s, Xij is the matrix of covariates for the first two PCs,
temperature, growth rate, and experimental batch, and μi is the vector of parameters
modeling the effects of genotype i of s on d. As pointed out in Choy et al. 2008 [3],
confounders such as growth rate need to be accounted for in analysis, and we found in the
current study that growth rate is a significant covariate. A summary of the association
analysis for the included covariates is found in Supplemental Table 3. Also, Np (0, Σ) is the
multivariate normal distribution, for vectors of length p = 6 and with mean 0 and variance Σ.
Significance of estimates for μi were assessed using Pillai’s trace [24]. Because association
tests rely on large sample asymptotic theory, only those loci that had at least 20 individuals
in each genotype group were retained for association mapping. This left 1,278,133 SNPs for
all drugs except 5-fluorouracil (971,593) and nilotinib (783,013).
Association tests were also performed for each drug family, as described in Table 1. For
this, the mean normalized viability across each dose-response curve was calculated for every
LCL and every drug. In this way, the model used for association of drug family d at an SNP
s also uses Equation 1, where Yij now represents the vector of mean normalized viabilities
(across all drugs in family d) for the jth individual having genotype i on s. All other variables
from Equation 1 remain the same, and p now equals the number of drugs in family d.
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Traditional p-value cut-offs for genome-wide significant and genome-wide suggestive levels
of association were used, motivated by standard practices in the field based on the effective
number of markers in the genome [25].
Drug clustering
Distance metrics between each pair of drugs were calculated from their vectors of
normalized viabilities, as in the association analysis. Specifically, the distance between
drugs a and b was calculated by first fitting:
where Yai and Ybi are the vectors of normalized viabilities for the ith LCL for drugs a and b,
respectively, and Xi is the corresponding matrix of covariates used in association mapping
(the first two PCs, experimental batch, temperature and growth rate). The coefficient of
partial determination (partial r-squared) of Ybi in predicting Yai after controlling for Xi was
calculated for all possible pairs (a,b). Distance between drugs a and b was estimated as:
where r2 (Ya , Yb |X ) (or r2 (Yb , Ya |X )) is the partial r-squared for a regressed on b (or b
regressed on a), after controlling for covariates X. Using this method, it was not possible to
include both 5-fluorouracil and nilotinib, since each cell line was exposed to exactly one of
these agents. For this reason, and because nilotinib had lower laboratory replicability (see
Supplemental Table 2), nilotinib was removed from clustering. The other 28 drugs were
clustered using the distance metric described above, using no a priori knowledge of drug
family. Clustering was performed using the matrix of distance metrics between all pairs,
described above, and the “hclust” function, with the argument “method=ward” from the R
statistical package [26]. To test whether this clustering was better than expected by chance,
permutation testing was performed, with 10,000 permuted samples created. For the
permutation, the tree is fixed and the drug name labels were permuted. Then the probability
of getting at least as many clustered drugs as was observed in each category by chance is
calculated. Probabilities less than 0.05 were considered statistically significant.
Consistency Analysis with Prior Linkage Results
While a direct validation/replication cohort is not readily available, to evaluate the
replication potential and overall stability of the results presented here, the overlap of the
association signals (at the suggestive level) from this study with the linkage peak from the
study that established the heritability of the drug response was evaluated [12]. The
percentage of suggestive variants from the current study that were located in a suggestive
linkage peak in the Peters et al. paper was calculated. Details of the linkage analysis can be
found in [12]. A SNP was considered to be within a linkage peak if the gene was within the
linkage peak as defined as described in the previous paper (using Ensembl to map genes to
the chromosomal locations).
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Manhattan plots illustrating the association mapping results for each of the 29 drugs are
given in Figure 1. In total, 18 SNPs reached a suggestive level of significance at p < 10−6
and are summarized in Table 2. Nine of these were located within a gene, and three were
within 100kbp of a gene (2 downstream and 1 upstream). In addition, Manhattan plots
illustrating the association mapping results for each of the 8 identified drug classes are given
in Figure 2. Of the four loci having a suggestive association (p < 10−6) with the vector of
mean normalized viabilities across a drug class, three occurred within or just upstream of a
gene (Table 3).
Drug clustering
Of the 28 different drugs investigated for clustering, 25 can be classified as members of one
of eight families, according to their similarity in structure and/or putative mechanism of
action (see Table 3). Clustering results are given in Figure 3. Drugs were considered to be
clustered together if they either were grouped in the same dendrogram branch (most
families), or if two drugs from neighboring branches were closer to each other than either
were to any other drug (temozolomide and mitomycin only). Overall, 18 of the 25 drugs
(72%) belonging to a family clustered very well according to that family. However, the
accuracy of the clustering algorithm differed substantially between drug families. Every
tubulin binding agent (either of the vinca alkaloid or taxol class), both tyrosine kinase
inhibitors, both platinum agents, both DNA alkylating agents, 4 out of 5 nucleosides and 3
out of 5 anthracyclines clustered together. On the other hand, the fluoropyrimidines
(floxuridine and 5-fluorouracil) and the podophyllotoxins (etoposide and teniposide) did not
cluster well. The results of the permutation testing reveal that these clustering results are
stronger than expected by chance for several of the drug classes (Nucleosides
p<0.0002950753; DNA alkylating agents p< 0.04761905; Platinum agents p< 0.04761905;
TK inhibitors p< 0.04761905; Anthracyclines p< 0.003958079; Tubulin binding agents
5.087505e-05).
Consistency with Prior Linkage Results
Our results show that 11 out of the 18 (61%) previous signals overlap with linkage peaks
from the previous study [12]. This is a substantial number, indicating that a number of these
signals are potentially reproducible. Referencing Table 2, the following SNPs were in
linkage peaks: 1, 2, 3, 7, 8, 10, 12, 13, 15, 17, 18. Surprisingly, the MGMT SNP was not
within a linkage peak, though this may reflect differences in power and assumptions
between the linkage and association studies.
Discussion
In the current study, we present the results of a large set of genome-wide association studies
performed using the LCL model system. We performed mapping for 29 drugs that had
previously shown modest to high heritability, and discovered a number of potential
associations. Importantly, the results recapitulated some genetic associations with known
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clinical relevance (including MGMT associations). This supports the potential of the model
system to rapidly identify genes of clinical importance. Of high interest, novel associations
were also seen in the results. While the clinical and functional relevance should be
investigated in future studies, there are a number of lines of evidence that support the
potential biological relevance of these findings. To our knowledge, this is the largest LCL
mapping study completed to date, and the overall quality of the data in such a high
throughput experiment was as high as previous, smaller studies [6-11].
Across all studies, 18 SNPs were found to have suggestive association (p < 10−6) for at least
one anticancer agent. Two thirds of these SNPs occurred within or nearby a gene, and many
of these genes have demonstrated functional relevance in previous studies. The strongest
association was between temozolomide and rs531572 (p < 10–15), located within the gene
O-6-methylguanine-DNA methyltransferase (MGMT). A separate publication [10] describes
this result in more detail, including MGMT ’s known ability to reduce the toxicity of
temozolomide, other polymorphisms within MGMT known to impact the clinical efficacy of
temozolomide, and a biologically meaningful relationship between rs531572 and MGMT
expression in LCLs.
Other associations also had meaningful clinical importance supported in the literature. Locus
rs12637988, associated with cytarabine response (p < 10−6), is located within the genes
mediator complex subunit 12-like (MED12L) and purinergic receptor P2Y, G-protein
coupled, 12 (P2RY12). MED12L previously has been associated with toxicity for LCLs
from an African cohort exposed to another chemotherapy agent (carboplatin) [6]. Locus
rs2270311 is associated with response to 5-fluorouracil (p < 10−6), and is located within
chimerin 2 (CHN2). Significant differences in the expression of CHN2 have been found
between colon cancer cells having different levels of 5-fluorouracil resistance [27]. Relevant
functions were less apparent for the other associated genes in Table 1.
The analysis across the drug families (Table 2) showed that locus rs7581424 is associated (p
< 10−6) with response to the alkylating class (temozolomide and mitomycin), and is
upstream of the gene histone deacetylase 4 (HDAC4). Possible interaction with DNA
alkylating agents may be especially interesting, as HDAC inhibitors are currently being
investigated in stage II clinical trials as agents to be used in combination with temozolomide
as therapy for glioblastoma patients [28]. Interestingly, there is no overlap in the genes
associated with the drug families and the individual drugs. This may indicate that there are
both private and shared signals between/amongst the drugs (though some of this may be due
to false positive findings from each either analysis).
These positive findings were obtained from a MANCOVA model. All analysis was
performed using the freely available software MAGWAS [16]. This model requires minimal
modeling assumptions, unlike traditional methods, which often assume the dose-response
curves follow a known form. In addition, this model makes no assumptions regarding the
differences in the dose-response curves between genotypes, in contrast to assuming that
differences are due to half-inhibitory concentrations or the slope of the non- linear curve. In
addition, this multivariate response approach allows for pooling information across dose
points. This advantage was exploited with the association across drug families, where
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information was pooled across drugs within a family. This allows for detection of weaker
signals that are not significant for each individually.
Because LCL dose response data may include a number of confounders [3], the choice of
appropriate QC techniques and association methods is vital for minimizing erroneous
inference and providing unbiased estimates in genetic mapping. Previous simulation studies
have demonstrated how a MANCOVA approach has superior power to detect signals, when
evaluated across a diverse set of differences in dose response curves between genotypes [17,
24].
In addition to identifying several important genes through association mapping, similarities
in LCL cytotoxicity profiles could be used to cluster drugs into appropriate groups based on
mechanisms of action, using no a priori knowledge, with high accuracy. This is consistent
with similar efforts using LCLs from multigeneration human families, that assessed
structure-function relationships within a chemical structural drug class [9] and across a
number of clinically used medications [12]. The ease of collecting LCL dose-response data
makes this clustering particularly attractive, since the mechanism of action of novel anti-
cancer agents may be discovered quickly and cheaply by testing together with other agents
that have well-understood biologic effects. Furthermore, since LCL response essentially
measures cytotoxicity, the clustering methods described here should be readily available for
toxicologic analysis. In this way, the types of toxicities for novel chemicals may be
discovered from screening together with other, better characterized chemicals.
As with any study, there are a number of limitations that need to be kept in mind in
interpreting these results. While these are exciting new candidates, additional follow-up
studies are needed. The large-scale nature of these experiments mean that concerns with
multiple testing should be considered. With the large number of drugs tested, it is clear that
the study is highly underpowered to consider more conservative cut-offs for significance
that account for all drugs tests. To try to address the reproducibility of these findings we
showed that there was substantial over-representation with these signals and a previous
linkage study, but true replication and validation studies are an important next step. In this
way, these results should be viewed as hypothesis generating, as opposed to hypothesis
testing. Additionally, the LCL model system, like any model system, is inherently limited in
it’s direct clinical relevance. The LCL drug response does not fully reflect the full
complexity of the clinical drug response. Excellent discussions of the limitations are
reviewed in [5].
Conclusions
Overall, the application of large scale discovery in LCL systems has promise for both
discovery of genes of putative mechanistic interest and for assessing distinct features of
agents across chemical structure in order to further the quest for rational drug therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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- Genome-wide association mapping in LCLs from unrelated Caucasians in 29 anti-
cancer agents reveal a number of novel associations.
- Among the single drug studies, suggestive associations were obtained for 18 loci,
12 within/near genes.
- Three of these gene associations, MED12L, CHN2 and MGMT, have been
previously implicated in cancer pharmacogenomics, reinforcing the potential of the
LCL model to reveal clinically useful genetic associations.
- The drug family association analysis resulted in 4 additional suggestive loci (3
contained within/near genes).
- Cluster analysis was performed to evaluate the potential of the cell line responses
to be similar due to similarity in the drug classes.
- The drug clustering results show that 18 of 25 drugs clustered into the appropriate
family.
- This study demonstrates the utility of LCLs for identifying genes having clinical
importance in drug response, for assigning unclassified agents to specific drug
families, and proposes new candidate genes for follow-up in a large number of
chemotherapy drugs.
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Manhattan plots for chemotherapy drugs.
SNPs with – log10 (p) > 6 are indicated with red vertical lines, and also summarized in
Table 1. Panel A represents arsenic trioxide, Panel B represents azacitidine, Panel C
represents carboplatin, Panel D represents cladribine, Panel E represents cytarabine, Panel F
represents dasatinib, Panel G represents daunorubicin, Panel H represents docetaxel, Panel I
represents doxorubicin, Panel J represents epirubicin, Panel K represents etoposide, Panel L
represents 5-fluorouracil, Panel M represents floxuridine, Panel N represents fludarabine,
Panel O represents gemcitabine, Panel P represents hydroxyurea, Panel Q rep- resents
idarubicin, Panel R represents mitomycin, Panel S represents mitoxantrone, Panel T
represents nilotinib, Panel U represents oxaliplatin, Panel V represents paclitaxel, Panel W
represents sunitinib, Panel X represents temozolomide, Panel Y represents teniposide, Panel
Z represents topotecan, Panel AA represents vinblastine, Panel AB represents vincristine,
Panel AC represents vinorelbine.
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Manhattan plots for families of drugs.
SNPs with – log10 (p) > 6 are indicated with red ver cal lines, and also summarized in Table
2. Panel A represents DNA alkylating agents, Panel B represents anthracyclines, Panel C
represents fluoropyrimidines, Panel D represents platinum agents, Panel E represents
nucleosides, Panel F represents epipodophylotoxins, Panel G represents tubulin binding
agents, Panel H represents TK inhibitors.
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Drug clustering using partial r-squared for viabilities between drugs, controlling for
laboratory covariates. Clustered groups are given in colored rectangles.
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Table 1
Drug family membership for 25 anticancer agents.
Drug Class Drugs
1 Nucleosides gemcitabine cytarabine cladaribine fludaribine azacitidine
2 TK inhibitors dasatinib sunitinib
3 Tubulin binding docetaxol pacitaxol vinblastine vincristine vinorelbine
4 DNA alkylating mitomycin temozolomide
5 Platinum agents carboplatin oxaliplatin
6 Anthracyclines daunorubicin doxorubicin epirubicin idaxubicin mitoxantrone
7 Fluoropyrimidines floxuridine 5-fluorouracil
8 Epipodophylotoxins etoposide teniposide
TK stands for tyrosine kinase.
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Table 2
Single nucleotide polymorphisms (SNPs) most associated with drug response, for each drug separately.
Drug Chrom. rsID −log10(p) Gene(s) nearby
1 Carboplatin 5 rs1982901 6.23 None
2 Cytarabine 3 rs12637988 6.21 MED12L / P2RY12
3 Daunorubicin 9 rs7867736 6.34 None
4 Etoposide 22 rs2076112 6.47 PLA2G6
5 Fluorouracil 7 rs2270311 6.23 CHN2
6 Fluorouracil 15 rs10152957 6.05 MEGF11
7 Gemcitabine 2 rs4851774 6.26 FHL2
8 Gemcitabine 3 rs513659 6.31 None
9 Idarubicin 2 rs7582313 6.87 None
10 Mitoxantrone 10 rs7068798 6.05 dC10orf67
11 Oxaliplatin 8 rs2897377 6.07 CSMD1
12 Oxaliplatin 17 rs1808918 6.01 dGNA13
13 Paclitaxel 1 rs1338990 6.33 None
14 Paclitaxel 4 rs306005 6.47 SPATA5
15 Paclitaxel 5 rs31878 6.86 None
16 Temozolomide 10 rs531572 15.48 MGMT
17 Teniposide 22 rs8138023 6.30 uNUP50
18 Topotecan 6 rs11966294 6.29 DDO
Superscripts u and d indicate that genes are located within 100kpb upstream or downstream of the SNP, respectively.
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Table 3
Single nucleotide polymorphisms (SNPs) most associated with drug response, for drug family.
Drug Class Chrom. rsID −log10(p) Gene(s) nearby
1 DNA Alkylating Agents 2 rs7581424 6.13 uHDAC4
2 DNA Alkylating Agents 16 rs11639947 6.55 NFAT5
3 Platinum Agents 10 rs10821910 7.84 C10orf107
4 TK Inhibitors 10 rs10762827 7.95 None
Superscripts u and d indicate that genes are located within 100kpb upstream or downstream of the SNP, respectively. TK stands for tyrosine kinase.
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